Tilray Brands Valuation
Is 2HQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2HQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2HQ (€1.58) is trading below our estimate of fair value (€3.75)
Significantly Below Fair Value: 2HQ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2HQ?
Key metric: As 2HQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2HQ's PS Ratio? | |
|---|---|
| PS Ratio | 1.9x |
| Sales | US$788.94m |
| Market Cap | US$1.47b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 52.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2HQ's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.7x | ||
THQM Tchaikapharma High Quality Medicines AD | 32.2x | n/a | лв1.6b |
SFA Sopharma AD | 0.5x | n/a | лв957.9m |
STAR Strides Pharma Science | 3.1x | 11.0% | ₹138.3b |
532482 Granules India | 3x | 13.7% | ₹132.2b |
2HQ Tilray Brands | 1.9x | 9.4% | €1.5b |
Price-To-Sales vs Peers: 2HQ is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (9.3x).
Price to Sales Ratio vs Industry
How does 2HQ's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 23 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 23 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 2HQ is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Pharmaceuticals industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is 2HQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 2HQ's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Novavax
US$1.3b
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
NVV1
US$6.70
7D
-21.8%
1Y
22.0%
Evotec
€1.8b
Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
EVT
€8.82
7D
0%
1Y
n/a
Valneva
€343.9m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
AYJ
€2.08
7D
-9.8%
1Y
-61.5%